• Earlier in June 2026, Vera Therapeutics announced that it had reached alignment with the U.S. FDA on a revised, earlier eGFR analysis plan for the ORIGIN 3 trial of atacicept in adults with IgA nephropathy, with key results now expected in the third quarter of 2026 to support a planned supplemental Biologics License Application in the fourth quarter of 2026.
• This regulatory alignment, informed by a National Kidney Foundation workshop and supported by ORIGIN Phase 2b eGFR data, clarifies how atacicept’s longer-term kidney function data could underpin its case for full approval in IgA nephropathy.
• We’ll now examine how the earlier ORIGIN 3 eGFR analysis timing may influence Vera Therapeutics’ investment narrative and risk profile.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Vera Therapeutics' Investment Narrative?

To own Vera Therapeutics, you need to be comfortable with a focused, high‑risk story built around atacicept in IgA nephropathy, funded by ongoing losses and regular capital raises. The newest FDA alignment on an earlier ORIGIN 3 eGFR analysis reinforces the centrality of atacicept and slightly reshapes the near term catalyst map: investors are now watching three closely linked events in quick succession, the July 2026 PDUFA decision, Q3 2026 eGFR readout, and a planned Q4 2026 sBLA filing. That timing tweak may not fundamentally change the thesis, but it concentrates regulatory and data risk into a tighter window while Vera has no revenue, a high cash burn, and a rich valuation on book value. The recent share price pullback highlights how sensitive the stock remains to execution.

However, one key risk around concentrated dependence on atacicept may surprise some investors. Vera Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Four Simply Wall St Community fair values for Vera range from about US$44 to a very large US$444, showing just how far apart private investors can be. Set against an earlier ORIGIN 3 eGFR readout that bunches catalysts together, this spread underlines why it can help to weigh several independent views before deciding how Vera might fit into a portfolio.

Explore 4 other fair value estimates on Vera Therapeutics - why the stock might be worth just $44.42!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Vera Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Vera Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vera Therapeutics' overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• Find 46 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.